Annual Report for the Financial Year 2025-2026 alongwith Notice of 42nd Annual General Meeting is attached herewith.

232/LG/SE/AUG/2026/GBSL August 12, 2026 To To BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra Kurla Complex, Dalal Street, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 509079 Scrip Symbol: GUFICBIO Subject: Annual Report for the Financial Year 2025-2026 along with the Notice of 42nd Annual General Meeting of the Company Dear Sir/Madam, This is to inform that the 42nd Annual General Meeting (“AGM”) of the Company is scheduled to be held on Friday, September 04, 2026 at 3.30 P.M. (IST) through Video Conference / Other Audio Visual Means (“VC/OAVM”) in accordance with the relevant circulars issued by Ministry of Corporate Affairs and Securities and Exchange Board of India. Pursuant to Regulation 34 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), we are submitting herewith the Annual Report of the Company including Business Responsibility and Sustainability Report for the Financial Year 2025-26 along with the Notice of the 42nd AGM. The Annual Report and the Notice of 42nd AGM are being sent to the members whose email-ids are registered with Depository Participants (DPs)/ Company/ RTA i.e. MUFG Intime India Pvt. Ltd., through electronic mode and the same are also uploaded on the Company's website at www.gufic.com. Further, in accordance with Regulation 36(1)(b) of the Listing Regulations, the Company will be sending a letter to those shareholders whose e-mail IDs are not registered with Company/DPs/RTA providing the web link including the exact path from where the Annual Report can be accessed. Kindly take the same on your record. Thanking you, Yours faithfully, For Gufic Biosciences Limited Ami Shah Company Secretary & Compliance Officer Membership No.: A39579 Encl.: As above global desnaon for injectables 42nd Annual Report 2025-2026 THE 1ST & ONLY COMPANY TO MANUFACTURE BOTULINUM TOXIN TYPE A INJ. IN INDIA GUFIC Research driven organisation BIOSCIENCES LIMITED In collaboration with in the field of botulinum neurotoxins l Proprietary Thin-Film Technology l Stable at 2o- 8o C for 14 days after reconstitution l Stable at 25o C for 6 months & 2o- 8o C for 36 months l Safety and Eficacy comparable to the Innovator brand - Proven by Split Face study on Indian Patients PEPTIDES Semaglutide Inj. 0.25mg / 0.5mg / 1.0mg Pen & Cartridge Semaglutide Injection For S. C. Use only For Single Patient Only Contains:1 pen & 6 disposable needles TABLE OF CONTENTS TABLE OF CONTENTS CORPORATE OVERVIEW CORPORATE INFORMATION 01 FINANCIAL HIGHLIGHTS 02 CHAIRMAN’S MESSAGE 03 BOARD OF DIRECTORS 05 STATUTORY REPORTS BOARD’S REPORT AND ITS ANNEXURES 06 REPORT ON CORPORATE GOVERNANCE 32 BUSINESS RESPONSIBILITY & SUSTAINABILITY REPORT 56 MANAGEMENT DISCUSSION & ANALYSIS REPORT 94 FINANCIAL STATEMENTS STANDALONE FINANCIAL STATEMENTS 122 CONSOLIDATED FINANCIAL STATEMENTS 184 CORPORATE INFORMATION FOUNDER Late Shri Pannalal S. Choksi BOARD OF DIRECTORS AS ON MARCH 31, 2026 Mr. Jayesh P. Choksi Chairman & Managing Director Mr. Pranav J. Choksi Chief Executive Officer & Whole Time Director Mr. Pankaj J. Gandhi Whole Time Director Dr. Anu S. Aurora Independent Director Mr. Kamal K. Seth Independent Director Mr. Akshya Kumar Mahapatra Independent Director KEY MANAGERIAL PERSONNEL (OTHER THAN DIRECTORS) Mr. Devkinandan B. Roonghta Chief Financial Officer Ms. Ami N. Shah Company Secretary & Compliance Officer STATUTORY AUDITOR COST AUDITOR SECRETARIAL AUDITOR Mittal Agarwal & Co. Poddar & Co. Manish Ghia & Associates BANKERS • The Saraswat Co-operative Bank Limited • UCO Bank • State Bank of India • Axis Bank Limited • HDFC Bank Limited • ICICI Bank Limited REGISTRAR AND TRANSFER AGENTS MUFG Intime India Private Limited (Formerly known as Link Intime India Private Limited) C- 101, Embassy 247, L.B.S. Marg, Vikhroli (West), Mumbai - 400 083 • Tel No: (022) 4918 6000 •Fax No: (022) 4918 6060 •Email: investor.helpdesk@in.mpms.mufg.com CORPORATE IDENTIFICATION NUMBER L24100MH1984PLC033519 REGISTERED OFFICE ADDRESS CORPORATE OFFICE ADDRESS 37, First Floor, Kamala Bhavan II, S. Nityanand Road, SM House, 11 Sahakar Road, Vile Parle (East), Andheri (East), Mumbai – 400 069, Maharashtra, India. Mumbai - 400 057, Maharashtra, India. • E-mail: corporaterelations@guficbio.com • Tel.: 022-6726 1000 • website: www.gufic.com • Fax: 022 - 6726 1067 / 68 PLANTS GUJARAT KARNATAKA MADHYA PRADESH Unit-1: Survey No. 195/3 and 171 Paiki, 703, Belgaum Industrial Estate, Smart Industrial Park, Plot no.48, National Highway No. 48, Near Grid, Udhyambag, Belgaum - 590008 Near NATRIP, Pithampur, Kabilpore Navsari - 396424, Gujarat Dhar- 454775, Madhya Pradesh Unit-2: Survey No. 171, National Highway No. 48, Near Grid Kabilpore, Navsari - 396424, Gujarat 42ND ANNUAL GENERAL MEETING DAY & DATE TIME MODE Friday, 04th September, 2026 03.30 P.M. Video Conferencing/ Other Audio Visual Means (VC/OAVM) FINANCIAL HIGHLIGHTS Revenue from 940.48 Operation (₨. in Crs.) 819.81 806.67 779.16 690.62 2022 2023 2024 2025 2026 EBITDA (₨. In Crs.) 152.93 148.82 148.05 138.60 137.22 2022 2023 2024 2025 2026 From the Desk of the Chairman & Managing Director “ What we register today is what we will earn from through the next decade” Dear Shareholders, The world has become less predictable. Trade routes are being redrawn. Tariffs move. Rules change with governments. A single playbook, applied across every country and every market, will no longer deliver good returns. What works in one market will not work in the next. This warrants a relook at how we go abroad, and we have begun it. Our international strategy will be broad-based. Many geographies, not a few. Going global, for Indian pharma, has so far meant a handful of large regulated markets, with everybody crowded into the same places. We will pursue growth across the whole of our footprint, with a specific strategy for each market: its own products, its own registrations, its own route to the customer. This is a good moment to be making the shift. The Government of India is working to globalise the Indian pharmaceutical franchise. Trade agreements are being signed with various countries as an initiative to boost the pharmaceutical sectors global presence. Each of them opens a door that was previously expensive to open. Gufic intends to be standing at each one, ready. Being ready means one thing above all. Registrations and intellectual property. We have therefore moved aggressively on regulatory and IP creation in the markets that matter to us, and we have a roadmap for it: country by country, product by product, with a sequence and a timeline against each. This is now our principal thrust. Global entry points. Front-end intellectual property. Registration and market access. Held in our own name, and not through somebody else's. We will invest further, and sizeably, in IP creation in the period ahead. I want to be clear about how we regard that spending. It is not a cost to be managed down. It is the asset we are building. What we register today is what we will earn from through the next decade. What we carry through those doors matters as much as the access itself. Our portfolio is deliberately narrow and deliberately differentiated. Complex injectables. Reproductive medicine. Therapies where few others choose to compete. We build and prove them at home, and then we take them out. Niche is not a limitation. In a world of many markets, it is how a company of our size wins any of them. The years ahead will be measured in approvals secured, dossiers filed and markets entered. That is the work, and it is already under way. My thanks to our people, to the clinicians who place their trust in our products, and to you, our shareholders, for your continued confidence and blessings. Yours faithfully, For Gufic Biosciences Limited Jayesh P. Choksi Chairman & Managing Director BOARD OF DIRECTORS Mr. Jayesh P. Choksi Chairman [Showing first 8,000 characters — download PDF for full document]